MedTrace Logo

A Phase 0 Study of AZD1775 in Recurrent GBM Patients

NCT02207010 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-12-10

No results posted yet for this study

Summary

This study would test how much of the new drug, AZD1775, is present in tumor, blood, and skin after one dose of the drug.

The purpose of the study is not to treat the tumor, but to see if the drug actually gets into the tumor cells. This study does not replace routine cancer treatment.

Conditions

Interventions

BIOLOGICAL

AZD1775

All patients receive a single dose of the oral study drug prior to surgery for resection of GBM.

Sponsors & Collaborators

  • The Ben & Catherine Ivy Foundation

    collaborator OTHER

  • American Society of Clinical Oncology

    collaborator OTHER

  • Barbara Ann Karmanos Cancer Institute

    collaborator OTHER

  • Translational Genomics Research Institute

    collaborator OTHER

  • St. Joseph's Hospital and Medical Center, Phoenix

    lead OTHER

Principal Investigators

  • Nader Sanai, MD · Barrow Neurological Institute at St.Joseph's Hospital Medical Center

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-12-31
Completion
2019-03-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02207010 on ClinicalTrials.gov